WAVE LIFE SCIENCES LTD. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
WAVE LIFE SCIENCES LTD. (WVE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.16 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-09
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$1.16M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$4.08M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$5.61M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$5.57M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$18.90M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$8.16M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$2.91M.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$257.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$1.16M 10-Q · filed 2018-05-09 | -$5.25M derived: sum of 2 quarters · filed 2018-05-09 | -$10.85M derived: sum of 3 quarters · filed 2018-05-09 | -$16.43M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | -$4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$9.69M derived: sum of 2 quarters · filed 2018-03-12 | -$15.26M derived: sum of 3 quarters · filed 2018-03-12 | -$18.90M 10-K · filed 2018-03-12 | |
| 2017-09-30 | -$5.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$11.18M derived: sum of 2 quarters · filed 2017-11-09 | -$14.81M 10-Q · filed 2017-11-09 | -$20.14M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-06-30 | -$5.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$9.21M 10-Q · filed 2017-08-09 | -$14.54M derived: sum of 3 quarters · filed 2018-05-09 | -$15.81M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-03-31 | -$3.63M 10-Q · filed 2018-05-09 | -$3.64M 10-Q · filed 2017-05-10 | -$8.96M derived: sum of 2 quarters · filed 2018-05-09 | -$10.24M derived: sum of 3 quarters · filed 2018-05-09 | -$11.11M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | -$5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$6.60M derived: sum of 2 quarters · filed 2018-03-12 | -$7.48M derived: sum of 3 quarters · filed 2018-03-12 | -$8.16M 10-K · filed 2018-03-12 | |
| 2016-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$2.15M derived: sum of 2 quarters · filed 2017-11-09 | -$2.83M 10-Q · filed 2017-11-09 | -$3.80M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-06-30 | -$874.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$1.56M 10-Q · filed 2017-08-09 | -$2.53M derived: sum of 3 quarters · filed 2018-03-12 | -$3.04M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-03-31 | -$685.00K 10-Q · filed 2017-05-10 | -$1.66M derived: sum of 2 quarters · filed 2018-03-12 | -$2.16M derived: sum of 3 quarters · filed 2018-03-12 | -$3.52M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2015-12-31 | -$970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$1.48M derived: sum of 2 quarters · filed 2018-03-12 | -$2.84M derived: sum of 3 quarters · filed 2018-03-12 | -$2.91M 10-K · filed 2018-03-12 | |
| 2015-09-30 | -$509.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$1.87M derived: sum of 2 quarters · filed 2016-11-09 | -$1.94M 10-Q · filed 2016-11-09 | -$1.95M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$1.43M 10-Q · filed 2016-08-15 | -$1.44M derived: sum of 3 quarters · filed 2017-03-16 | ||
| 2015-03-31 | -$72.00K 10-Q · filed 2016-05-16 | -$81.00K derived: sum of 2 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$257.00K 10-K · filed 2017-03-16 | |||
| 2014-09-30 | -$248.00K 10-Q · filed 2015-12-17 | ||||
| 2013-12-31 | -$47.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |